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Abstract
Background:  Sporadic Parkinson's disease (sPD) is a nervous system-wide disease that presents with a
bradykinetic movement disorder and is frequently complicated by depression and cognitive impairment. sPD likely
has multiple interacting causes that include increased oxidative stress damage to mitochondrial components and
reduced mitochondrial bioenergetic capacity. We analyzed mitochondria from postmortem sPD and CTL brains
for evidence of oxidative damage to mitochondrial DNA (mtDNA), heteroplasmic mtDNA point mutations and
levels of electron transport chain proteins. We sought to determine if sPD brains possess any mtDNA genotype-
respiratory phenotype relationships.
Results: Treatment of sPD brain mtDNA with the mitochondrial base-excision repair enzyme 8-oxyguanosine
glycosylase-1 (hOGG1) inhibited, in an age-dependent manner, qPCR amplification of overlapping ~2 kbase
products; amplification of CTL brain mtDNA showed moderate sensitivity to hOGG1 not dependent on donor
age. hOGG1 mRNA expression was not different between sPD and CTL brains. Heteroplasmy analysis of brain
mtDNA using Surveyor nuclease® showed asymmetric distributions and levels of heteroplasmic mutations across
mtDNA but no patterns that statistically distinguished sPD from CTL. sPD brain mitochondria displayed
reductions of nine respirasome proteins (respiratory complexes I-V). Reduced levels of sPD brain mitochondrial
complex II, III and V, but not complex I or IV proteins, correlated closely with rates of NADH-driven electron
flow. mtDNA levels and PGC-1α expression did not differ between sPD and CTL brains.
Conclusion: PD brain mitochondria have reduced mitochondrial respiratory protein levels in complexes I-V,
implying a generalized defect in respirasome assembly. These deficiencies do not appear to arise from altered
point mutational burden in mtDNA or reduction of nuclear signaling for mitochondrial biogenesis, implying
downstream etiologies. The origin of age-related increases in distribution of oxidative mtDNA damage in sPD but
not CTL brains is not clear, tracks with but does not determine the sPD phenotype, and may indicate a unique
consequence of aging present in sPD that could contribute to mtDNA deletion generation in addition to mtDNA
replication, transcription and sequencing errors. sPD frontal cortex experiences a generalized bioenergetic
deficiency above and beyond aging that could contribute to mood disorders and cognitive impairments.
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Background
Parkinson's disease (PD) is the most commonly occurring
neurodegenerative movement disorder of adults and
occurs sporadically (sPD) in >90% of cases. sPD is now
recognized to be a nervous system-wide disorder with a
temporal progression of protein aggregation pathology
that begins in gut enteric neurons, then enters vagal and
olfactory neurons before appearing in midbrain substan-
tia nigra [1-6]. Death of nigral dopaminergic neurons her-
alds the onset of the diagnostic bradykinetic movement
disorder, while pathology continues to spread rostrally
into limbic and eventually frontal cortex. Recent data are
consistent with early functional cerebral cortical involve-
ment that precedes cortical Lewy pathology [7]. Less
intense neurodegeneration in locus coereuleus and mid-
brain raphe nuclei, combined with cortical Lewy neurite
and Lewy body formation, likely contribute to the fre-
quent comorbidities of depression and cognitive impair-
ment seen in many sPD patients [8].
Currently five monogenic causes of parkinsonism are
known that produce clinical phenotypes variably similar
to, and in some cases virtually identical with sPD [9-11].
Mechanisms of pathogenesis in these autosomal genetic
forms of parkinsonism appear to include disruptions of
mitochondrial morphology and function [12,13]. In sPD
a substantial body of work has demonstrated associations
in brain and peripheral tissues with impaired mitochon-
drial bioenergetics and increased oxidative stress [14,15].
Although the causality of mitochondrial deficits for con-
tributing to human sPD pathogenesis is not proven, a
compelling rodent model of nigral dopaminergic degen-
eration and protein aggregation reminiscent of Lewy
pathology is observed after chronic systemic treatment
with rotenone, a mitochondrial electron transport chain
poison that inhibits electron transfer at the ubiquinone
reduction site in complex I [16,17]. Rotenone toxicity to
mammalian cultured cells [18] or rat dopaminergic neu-
rons [19] derives from increased oxidative stress and is
eliminated by expression of a yeast complex I insensitive
to rotenone, implying that rotenone neurodegeneration
in vivo derives from oxidative stress generated at complex
I. Thus, sPD and monogenic parkinsonisms appear to
share disrupted mitochondrial function with altered
bioenergetics as common characteristics that are poten-
tially pathogenic.
Assessing mitochondrial bioenergetic function and conse-
quences of bioenergetic inefficiency is limited in frozen
postmortem sPD brain. Traditionally, maximal catalytic
activities of individual ETC complexes have been assayed,
yielding a frequent finding that complex I activity is
reduced. However, these assays of isolated complex activ-
ities do not necessarily provide insight into respiratory
capacity, coupling of respiration to ATP synthesis and rate
of production of reactive oxygen species (ROS). Freezing
disrupts mitochondrial capacity to generate proton gradi-
ents across the inner membrane, which are necessary for
ATP synthesis and are inversely related to ROS produc-
tion.
In our earlier work we used complex I immunocapture
antibodies to show that sPD brain mitochondria had ele-
vated oxidative damage to several complex I proteins, and
that the levels of these oxidized complex I subunit pro-
teins inversely correlated with NADH-driven electron flow
[20]. These results suggested that the increased oxidative
damage to complex I proteins in sPD brains were causally
involved in slowing NADH-driven electron flux. We also
showed that exposure of CTL mitochondria to high
[NADH] produced oxidative damage to complex I pro-
teins similar to what we found in sPD samples. This sug-
gested that at least some of the complex I oxidative
damage could be internally generated.
In the present study we have extended our analysis to
measure in sPD brain mitochondria the levels per unit
mitochondrial mass of multiple ETC proteins that are
believed to functionally associate with each other in a res-
piratory unit known as the "respirasome" [21,22].
Because these ETC proteins from all five complexes were
reduced in sPD brain mitochondria, we explored whether
abnormalities in sPD mtDNA could account for this defi-
ciency. We used a mismatch-cleaving endonuclease (Sur-
veyor®) to search for low-abundance heteroplasmic
mutations in multiple overlapping PCR fragments of sPD
mtDNA [23,24]. Finally, we quantified the distribution of
oxidative mtDNA lesions in sPD brain by assessing inhi-
bition of qPCR amplification by treatment with the DNA
glycosylase hOGG1, a component of the mitochondrial
base excision repair pathway. We found that neither
mtDNA heteroplasmic mutation abundances nor oxida-
tive mtDNA damage provided insight into why sPD
respirasome assembly appears defective. In addition, lev-
els of reduced sPD brain mitochondrial respiratory pro-
teins from complexes II, III and V correlated closely with
rates of NADH-driven electron flow, implying a func-
tional relationship to respirasome function.
Results
Postmortem brain samples
Clinical histories, cause of and age at death, sex, and post-
mortem interval between death and dissected sample
placement into -80°C freezer are shown in Additional
Files 1 for CTL and 2 for sPD. The average age at death for
CTL samples was 67.0 ± 13.4 years and for sPD samples
was 77.8 ± 4.9 years with no significant difference (p =
0.08). CTLs consisted of 7 males and 3 females (70%
males) and the sPDs were composed of 5 males and 3
females (62.5% males) with no significant difference (p =Molecular Neurodegeneration 2009, 4:37 http://www.molecularneurodegeneration.com/content/4/1/37
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0.73). Postmortem interval for CTLs was 8.65 ± 4.77
hours and for sPDs 12.66 ± 4.15 hours (p = 0.11). (Addi-
tional File 3)
ETC Complex I Subunits Are Significantly Reduced in sPD 
Frontal Cortex
Figure 1 shows the results of Western blot assays for ETC
subunits of Complex I in sPD and CTL brain mitochon-
dria. Band integrated intensities in each sample were nor-
malized against mitochondrial porin, an abundant outer
mitochondrial membrane protein, in each sample as a
marker for mitochondrial mass. The porin-normalized
CTL values were averaged, and each individual sPD or CTL
subunit level was expressed as a percentage of mean CTL.
A two-way analysis of variance across all the subunits of
Complex I showed a significant difference between CTL
and sPD samples (p = 0.0003). Individual comparison of
each Complex I subunit for CTL versus sPD showed a sig-
nificant difference in the 30 kDa subunit (p = 0.043), 15
kDa subunit (p = 0.042), and 8 kDa subunit (p = 0.026)
using the Mann-Whitney Test. Figure 1 shows that the 8
kDa and 15 kDa subunits in sPD were reduced by 80% of
the corresponding CTL subunit values, with the 39 kDa
subunit showing the least reduction (~30%) in sPD in
comparison to CTL.
ETC Complex II-V Subunits Are Significantly Reduced in 
sPD Frontal Cortex
Figure 2 shows the results of Western blot assays for ETC
subunits of Complexes II-V in sPD and CTL brain mito-
chondria, normalized to porin and expressed as percent-
age of mean CTL. A two-way analysis of variance across
Complexes II - V showed a significant difference between
CTL and sPD samples (p = 0.011). Individual comparison
of CTL versus sPD showed a significant difference in Com-
plex IV (p = 0.027) using the Mann-Whitney Test. Figure
2 shows a ~50% reduction in Complex IV and Complex V
for sPD in comparison to CTLs. Complex II and Complex
III show ~20% reduction in sPD versus CTLs.
Levels of sPD Complex II, III and V Protein Subunits are 
Inversely Related to NADH-driven Electron Flux Rate
In our previous work we made mitochondrial prepara-
tions from many of the same sPD postmortem cortex sam-
ples used in the present study and incubated them with
NADH to initiate electron flow through complex I [20].
We used a SOD1-peroxidase-Amplex Red system to detect
electrons that left the ETC and reduced oxygen to superox-
ide. We found that these rates of NADH-driven electron
flux were reduced in sPD brain mitochondria and were
inversely related to amounts of oxidatively damaged com-
plex I protein subunits. Figure 3 shows that these rates of
Levels of Complex I subunit proteins in sPD brain mitochon- dria Figure 1
Levels of Complex I subunit proteins in sPD brain 
mitochondria. Individual protein band intensities were nor-
malized to porin intensity in each sample and expressed in 
terms of mean CTL levels. A 2-way ANOVA across subunits 
and disease showed a significant interaction. Mann-Whitney 
test showed significant reductions for 30 kDa, 15 kDa and 8 
kDa subunits in sPD samples.
Levels of representative subunit proteins from Complexes II- V in sPD brain mitochondria Figure 2
Levels of representative subunit proteins from Com-
plexes II-V in sPD brain mitochondria. Individual pro-
tein band intensities were normalized to porin intensity in 
each sample and expressed in terms of mean CTL levels. A 2-
way ANOVA across subunits and disease showed a signifi-
cant interaction. Mann-Whitney test showed significant 
reductions for Complex IV subunit in sPD samples.Molecular Neurodegeneration 2009, 4:37 http://www.molecularneurodegeneration.com/content/4/1/37
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NADH-driven electron flow were very highly correlated
with levels of protein subunits from complexes II, III and
V that are coded for by nuclear genes, but not from com-
plex IV that is coded for by mtDNA. There were no corre-
lations among NADH-driven electron flow rates and
levels of any complex I protein subunits (Additional
File 4).
mtDNA Heteroplasmy Analysis Fails to Distinguish sPD 
from CTL mtDNA's
We used a Surveyor®  mismatch-cleaving nuclease
approach to estimate relative burdens of low abundance
heteroplasmic mutations in sPD and CTL brain mtDNA
samples [23,24]. The principle behind this approach is
that after PCR amplification, denatured single strands
with low-abundance heteroplasmic mutations are statisti-
cally more likely to hybridize with strands containing the
w.t. sequences. The resulting base mismatches are cleaved
with Surveyor®  nuclease, yielding products whose size
indicates the mutation's distance from one or the other
primer sites of the PCR product amplified. This approach
provides an efficient "survey" of heteroplasmic mutation
numbers, abundances and sizes but only estimates loca-
tion and does not define specific base alterations of each
mutation.
Since all of our PCR products were ~2 kbases in size, we
report results from Surveyor-cleaved products of 1000-
1900 bp. In this manner we hoped both to minimize
inclusion of bands that could represent the same muta-
tion and heteroplasmies in the ~50-100 bp primer over-
laps. By varying the proportion of heteroplasmy in
Correlations among levels of Complexes II, III and V and NADH-driven electron flux rates in sPD brain mitochondria Figure 3
Correlations among levels of Complexes II, III and V and NADH-driven electron flux rates in sPD brain mito-
chondria. NADH-driven electron flux rates for mitochondria isolated from frontal cortex of the same cases were taken from 
data described in Keeney, et al. Porin-normalized levels of respiratory proteins were determined as described in Methods.Molecular Neurodegeneration 2009, 4:37 http://www.molecularneurodegeneration.com/content/4/1/37
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plasmid sequences provided by the manufacturer, we
found that our system could reliably detect heteroplasmic
mutation abundances at the 2% level (Additional File 5).
The approximate location of primers A-H on the mito-
chondrial genome are shown in Additional File 6.
With this technique we found in their mtDNA's covered
by the A-H primers an average of 19.0 heteroplasmies/
brain in six sPD brains and 19.5 heteroplasmies/brain in
six CTL brains. Figure 4 shows the distribution across
primers of detected heteroplasmies and their levels from
our sPD and CTL brain mtDNA's analyzed using the Sur-
veyor®  nuclease approach. Two-way, non-parametric
ANOVA across the variations of heteroplasmy levels and
disease (sPD, CTL) for primers A-H did not reveal any sig-
nificance for either variation (levels: F = 0.62, p = 0.74;
disease: F = 1.90, p = 0.17) or their interaction (F = 1.10,
p = 0.37).
8-oxoG Distribution Increases with Age in Human sPD 
Postmortem Brain
We estimated in mtDNA from our brain samples the dis-
tribution of 8-oxoG residues, a most commonly formed
oxidized nucleoside derivative that is increased in mtDNA
of vulnerable PD nigral neurons [25]. We utilized an
approach whereby DNA isolated from brain mitochon-
dria was treated with human oxyguanosine glycosylase-1
(hOGG1), a component of the base-excision repair path-
way that removes oxidized guanosines and creates single-
strand breaks. After single-strand breaks are created, DNA
polymerase will stall and PCR amplification will be inhib-
ited.
Figure 5 shows the proportion of mtDNA retained after
hOGG1 digestion following amplification by primer pairs
A-H for each CTL and sPD sample. This value was
obtained by dividing the qPCR calculated starting quan-
tity (SQ) of sample treated with hOGG1 by the SQ of the
same sample undigested by hOGG1. CTL samples showed
mtDNA insensitive to hOGG1 from 20-80%, with greatest
density of overlap at 30-60% of the genome retained.
Amount of oxidative damage did not correspond to age at
death in CTLs (Figure 5A) that was observed with the PD
samples (Figure 5B). The sPD samples showed a wider
range of relative amount of 8-oxoG oxidation from 0-90%
of the mtDNA insensitive to hOGG1. Most interestingly,
the level of 8-oxoG oxidation corresponded to increased
age at death, with one exception. The eldest patient (age
84), exhibited almost complete oxidation of the mito-
chondrial genome across primers A-H, while the youngest
patient (age 72) showed the least amount of oxidation in
the sPD group. We did not find any correlation between
apparent 8-oxoG distribution across mitochondrial
genomes and levels of mtDNA heteroplasmies in either
CTL or sPD brain samples (not shown).
mtDNA copy numbers and PGC-1α expression are not 
altered in sPD brains
To search for evidence of alterations in mitochondrial bio-
genesis we assayed with qPCR levels of mtDNA copy
number in genomic DNA and PGC-1α expression in
cDNA from sPD and CTL brain homogenates (Figure 6).
We did not detect any differences, and there was a non-
significant trend for PGC-1α expression to be increased in
sPD (Figure 6B). PGC-1α expression and mtDNA levels
exhibited a rectangular hyperbolic relationship to each
other (Figure 6C).
Discussion
A fundamental limitation of postmortem brain studies in
a neurodegenerative disease such as sPD is that the pri-
mary tissues analyzed result from "uncontrolled experi-
ments". Individuals develop sPD at different ages for
unclear reasons, are treated with variable doses of symp-
tomatic drugs for varying time intervals, have different
additional environmental exposures and lifestyles, pos-
sess individualized genetic backgrounds and die across a
spectrum of ages from processes that may or may not be
physiologically related to their sPD. What joins these
specimens together in a study such as this one is the
appearance of a similar clinical phenotype and the pres-
ence of common neuropathological abnormalities such as
nigral cell death and Lewy body aggregates. However, that
those similar clinical and pathological phenotypic charac-
teristics exist does not require common etiologies either
across individuals or disease stages. The recent discoveries
of multiple monogenic parkinsonisms that share pheno-
typic properties with sPD and derive from mutations in
seemingly disparate genes provide excellent examples of
how similar neurodegenerative phenotypes can be caus-
ally distinctive. There is no reason to assume that the
causes of sPD will be any less diverse.
In addition, most postmortem sPD brain samples are
from persons who died in relatively advanced disease
stages. Abnormalities uncovered in these specimens can-
not be assumed to represent "genesis" events in disease
origin. Further, sPD is an anatomically progressive disease
across the entire neuraxis that is beginning to involve lim-
bic and frontal cortex at the time nigral degeneration has
progressed to yield the earliest clinical symptoms
[2,4,5,7]. Abnormalities uncovered in these more rostral
brain regions may or may not reflect molecular events
related to nigral neurodegeneration, but we and others
feel that loss of these dopaminergic neurons should
longer be the sole focus of sPD investigations [26,27].
In this context, and considering these caveats, our results
provide additional support to a view of sPD that considers
mitochondrial dysfunction to be a substantial component
of pathological progression [10,12,13,15,28]. Based onMolecular Neurodegeneration 2009, 4:37 http://www.molecularneurodegeneration.com/content/4/1/37
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Distributions of heteroplasmic mutations in sPD and CTL brain mtDNA Figure 4
Distributions of heteroplasmic mutations in sPD and CTL brain mtDNA. mtDNA's from six sPD and six CTL brains 
were amplified using primer pairs A-H. The amplicons were subject to Surveyor Nuclease treatment and separation/analysis of 
products using Experion 12K DNA chips. Bands from 1000-1900 bp size are included in the Figure. The Y-axes are DNA levels 
and X-axes are product sizes in bp.Molecular Neurodegeneration 2009, 4:37 http://www.molecularneurodegeneration.com/content/4/1/37
Page 7 of 13
(page number not for citation purposes)
findings presented here, we propose three concepts: 1.
sPD brain mitochondria eventually experience substantial
misassembly of the respirasome, the proposed macro-
assembly of complexes I-V that forms the functional unit
of electron transport and ATP synthesis [21,22]. We did
not find evidence of reduced mitochondrial biogenesis
signaling as an etiology of decreased respirasome assem-
bly; 2. sPD brain mtDNA undergoes an age-related
increase in distribution of oxidative damage. This mtDNA
damage is not necessary for the sPD phenotype, but it may
contribute to appearance of age-related deficits in sPD
such as cognitive impairment; 3. The Surveyor nuclease
approach does not provide any evidence for low abun-
dance heteroplasmic mtDNA mutations in brain as being
associated with the sPD phenotype.
In our analysis of brain mitochondria isolated from PD
frontal cortex, the normalized abundances of multiple
subunits of Complex I examined were significantly
reduced in comparison to CTLs. By normalizing to a mito-
chondrial mass marker (porin), we demonstrated that the
8 kDa, 15 kDa, and 30 kDa subunits were significantly
Distribution across mtDNA of inhibition of PCR amplifica- tion from treatment with hOGG1 as a function of donor age Figure 5
Distribution across mtDNA of inhibition of PCR 
amplification from treatment with hOGG1 as a func-
tion of donor age. mtDNA's from CTL and sPD brains 
were treated with hOGG1 and amplified with qPCR and 
primer pairs A-H. Shown are the proportional amplification 
for each sample and each primer pair. sPD samples showed 
(with one exception) an age-related in increase of hOGG1 
sensitivity not seen in CTL samples. Donor ages for each 
sample are shown on the right.
Levels of mtDNA and PGC-1α expression in sPD and CTL  brain homogenates Figure 6
Levels of mtDNA and PGC-1α expression in sPD and 
CTL brain homogenates. mtDNA D-loop was assayed 
with qPCR in genomic DNA's and PGC-1α expression was 
assayed with qPCR in cDNA's derived from sPD and CTL 
brain total homogenates and normalized to 18S rRNA levels. 
Their relationship was best described by a two-variable rec-
tangular hyperbola shown in C.Molecular Neurodegeneration 2009, 4:37 http://www.molecularneurodegeneration.com/content/4/1/37
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decreased in sPD brain mitochondria. In our earlier work,
only the 8 kDa subunit was significantly reduced, but no
normalization to mitochondrial mass was utilized. In the
present study we normalized each individual sample's
ETC protein levels to the porin signal in that specific sam-
ple. In this manner, the relative ETC protein levels could
be analyzed as a function of an abundant marker for mito-
chondrial mass.
The deficiency of the nuclear encoded 30 kDa subunit of
Complex I, known as NADH deydrogenase (ubiquinone)
iron-sulfur protein 3 (NDUFS3), is especially intriguing
since this subunit is known to be catalytically active in the
iron sulfur moiety of Complex I and critically involved in
Complex I assembly [29,30]. The 15 kDa subunit known
as NADH dehydrogenase (ubiquinone) 1 beta subcom-
plex subunit 4 (NDUFB4) is part of the hydrophobic pro-
tein fraction of Complex I and is notable for being one of
the Complex I subunits post-translationally modified by
peroxynitrite [31]. In cells from patients with a variety of
Complex I deficiencies, reductions in levels of 8 kDa and
15 kDa Complex I subunits correlated better with reduced
catalytic activity than did the levels of other Complex I
subunits [32]. Overall our results confirm and extend ear-
lier findings that complex I is misassembled, deficient,
and dysfunctional in sPD brain mitochondria [20].
Our quantitative immunoblot study of representative
members of the respirasome from mitochondria isolated
from the same frontal cortex samples indicated a more
widespread reduction of complexes II-V. When each com-
plex was analyzed individually versus CTLs, the cyto-
chrome c oxidase subunit 2 of Complex IV was
significantly reduced (p = 0.027). This subunit is encoded
by mtDNA and is one of three catalytic units composing
the inner core of Complex IV.
The widespread reduction of multiple members of com-
plexes I-V in sPD frontal cortex, combined with the highly
correlated relationships among levels of complexes II, III
and V with NADH-driven electron flux rates, suggest that
the entire respirasome is deficient. Respirasomes are
viewed as macromolecular assemblies of individual ETC
complexes, that themselves are assemblies of multiple
ETC protein subunits [21,22]. The details of respirasome
assembly remain to be established, but the evolving pic-
ture is that defects in individual ETC protein subunits can
disrupt assembly of that subunit's complex, which in turn
interferes with normal respirasome assembly [22]. It is
conceivable that the substantial deficiencies we found in
Complex I subunits could be responsible for more exten-
sive respirasome assembly defects. However, until more is
known about the processes that facilitate and hinder
respirasome assembly, our proposal remains speculative.
We admit that our assessment is based on indirect meas-
urements of respirasome function, since coupled respira-
tion is absent in frozen postmortem mitochondria. If
indeed present, dysfunction of the respirasome may lead
to inefficient formation of the proton gradient across the
inner mitochondrial membrane needed by ATP synthase
(Complex V) to create ATP, the cell's major metabolic
fuel.
Our analysis of 8-oxoG distribution within the mitochon-
drial genome in sPD frontal cortex showed that the older
cases had extensive 8-oxoG oxidation in each ~2 kbase
amplicon from primers A-H (Figure 3). It is known that
the presence of 8-oxoG in DNA can lead to a G → T trans-
versions in DNA replication. Even more relevant, Brégeon
et al. showed that non-dividing E. coli DNA containing 8-
oxoG could cause transcriptional mutagenesis [33,34]. By
cDNA sequencing obtained from mRNA transcripts, this
group found that RNA polymerase incorrectly incorpo-
rated adenine across from 8-oxoG lesions [33]. They also
discovered that 8-oxoG lesions could cause RNA polymer-
ase slippage resulting in a single mRNA base deletion
leading to frameshift mutations of the transcript [33]. It is
theorized that these incorrectly transcribed mRNAs could
lead to misfolded, dysfunctional, and reduced abundance
of functional protein within these non-dividing cells. This
theory potentially links our study's observation that 8-
oxoG content in sPD mtDNA could be correlated to our
observed reduction of the ETC respirasome protein subu-
nits in PD frontal cortex. However, our study did not
quantify the extent of 8-oxoG damage, but rather demon-
strated increased distribution of 8-oxoG within the major-
ity of the coding regions of mtDNA.
In human cell DNA replication 8oxoG:A mismatches are
repaired more slowly than 8oxoG-C, resulting in
increased mutagenicity from G-T transversions [35,36].
This mutagenicity of 8-oxoG may derive the ability of
8oxoG:A pairs to "fool" proofreading mechanisms of
DNA polymerase [37]. This mismatch phenomenon
brings in to question the fidelity of DNA sequencing
methods that use prokaryotic polymerases such as the
dideoxy DNA sequencing method. This method is often
used when performing mtDNA heteroplasmy analyses.
Because any guanine residue within the mitochondrial
genome can be oxidized to 8-oxoG and thus base pair
with both cytosine and adenine, some heteroplasmy anal-
yses not adjusting for this phenomenon might show a
greater mtDNA heteroplasmy than actually exists. Further
studies would help to elucidate whether this miscoding
phenomenon significantly has affected mtDNA hetero-
plasmy analyses.
Our study also showed that the prevalence of oxidatively
damaged 8-oxoG residues increased with age in PD andMolecular Neurodegeneration 2009, 4:37 http://www.molecularneurodegeneration.com/content/4/1/37
Page 9 of 13
(page number not for citation purposes)
not in CTL mtDNA. The presence of 8-oxoG damage did
not act as a biomarker of sPD however, because many of
the CTL samples had a considerable proportion of
mtDNA containing 8-oxoG lesions. Several sPD samples
also had relatively low distributions of 8-oxoG damage.
Increased age and increased 8-oxoG levels in both mtDNA
and nDNA have been linked in a study by Lezza et al. who
examined cerebral cortex from normal human brain, and
found that 8-oxoG levels were significantly increased in
the cohort over the age of 70 as compared to cases below
70 years of age [38]. Alam et al. discovered a significant
correlation between PD and increased levels of 8-oxoG
when compared to healthy CTLs in substantia nigra [39].
Fukae et al. showed a significant increase in the percent-
ages of nigral neurons immunoreactive to hOGG1-2a in
PD when compared to neurons in substantia nigra of
CTLs, progressive supranuclear palsy, and corticobasal
degeneration cases [40]. This group later reported an
increase in mitochondrial hMUTYH in sPD substantia
nigra [41]. This enzyme removes mismatched adenines
incorporated opposite 8-oxoG during replication mis-
match.
Our findings complement those of Zhang et al [42]. Using
immunohistochemistry for 8-oxoG, they found notable
increases of cytoplasmic immunostaining in nigral neu-
rons of sPD brains. The immunostaining was reduced by
pretreatment with either DNAase or RNAase and was
eliminated by pretreating with both enzymes. Their find-
ings support the presence of increased levels of both mito-
chondrial DNA and RNA oxidative damage in sPD nigral
neurons.
Taken together, these findings suggest a complicated inter-
play between mtDNA oxidation, aging, and the develop-
ment of sPD; increased aging and 8-oxoG damage may be
two of many factors involved in the etiology of this dis-
ease. Furthermore, the increases in hOGG1-2a in PD
nigral neurons and hMUTYH in PD nigral mitochondria
may demonstrate a neural compensatory mechanism
when faced with increased oxidative stress damage to
mtDNA.
Conclusion
Our studies showed that sPD brain mitochondria from
frontal cortex have a generalized deficiency of respirasome
protein components. This finding implies a more diffuse
mitochondrial bioenergetic deficit than proposals that
discuss sPD as primarily possessing a deficiency at one
ETC complex. We do note, however, that the greatest
losses of respirasome proteins were several Complex I
subunits. Thus, the functional, catalytic deficiencies found
in sPD brain may be greatest at complex I, even though
the larger respirasome assembly is impaired more gener-
ally at the molecular level.
Could sPD brain mtDNA be causally responsible for a
more generalized respirasome deficit? Although our study
does not provide any supportive evidence for this possi-
bility, we note that our studies of sPD cybrid models have
shown generalized deficiencies of multiple respirasome
proteins apparently due to reduced mitochondrial bio-
genesis signaling [43]. Our findings in sPD cybrids suggest
that mtDNA deficiency could be a contributing factor, but
we note that in our current study, sPD brain mtDNA levels
were not reduced, nor was there any evidence of decreased
mitochondrial biogenesis signaling.
Finally, we note that we studied mitochondria purified
from total brain homogenates; thus, the majority of mito-
chondria are likely from non-neuronal cells. It will be of
value to attempt similar studies in isolated sPD brain neu-
rons, once proteomic sensitivity has improved to allow
single cell analyses.
Methods
Isolation of gradient purified mitochondria from human 
cerebral frontal cortex
Human cerebral frontal cortex samples were obtained
from the Brain Resource Facility at the University of Vir-
ginia Health System. Mitochondrial isolation was per-
formed on sPD samples (diagnosis confirmed
histologically; N = 8) and age-matched controls (CTL, N =
10). Gradient purified mitochondria were obtained via a
modified protocol developed by Lai and Clark [25]. 2-3
grams of frontal cortex stored at -80°C were minced in 3
mL mitochondrial isolation buffer (MIB; 0.15 M KCl, 20
mM monopotassium phosphate, 1 mM EDTA, pH 7.6)
and homogenized by 60 passes with Dounce homogeniz-
ers in an additional 9 mL MIB. The homogenate was cen-
trifuged for 3 min at 1300 × g. The supernatant was
removed from the pellet and stored on ice. The pellet was
resuspended in 5 mL MIB and homogenized via 30 addi-
tional passes of the Dounce homogenizers. 6 mL MIB was
added to this second homogenate, which was again cen-
trifuged at 1300 × g. This second supernatant was added
to the originally isolated supernatant and centrifuged for
20 min at 17,000 × g at 4°C. The supernatant was
removed and discarded. The pellet was resuspended in 30
mL MIB and centrifuged again for 20 min at 17,000 × g at
4°C. The supernatant was removed and discarded leaving
a crude mitochondrial fraction.
The pellet was resuspended in 5 mL of gradient purified
mitochondrial isolation buffer (GPMIB; 0.15 M KCl, 20
mM monopotassium phosphate, 1 mM EDTA, 5.5 mM 2-
mercaptoethanol, 1 mM phenylmethanesulphonyl fluo-
ride, 10% v/v of 100 × protease inhibitor cocktail from
CalBioChem, pH 7.6) and homogenized with a Teflon
glass homogenizer. A Ficoll solution gradient was con-
structed via pouring 10 mL of a 7.5% Ficoll w/w solutionMolecular Neurodegeneration 2009, 4:37 http://www.molecularneurodegeneration.com/content/4/1/37
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over 12 mL of a 10.0% Ficoll w/w solution. The crude
mitochondrial fraction homogenate was poured over the
Ficoll gradient and centrifuged for 37 min at 28,000 RPM
at 4°C. The Ficoll solution gradient was decanted from the
gradient purified mitochondrial pellet. The pellet was
divided and stored at -80°C in modified radioimmuno-
precipitation buffer (RIPA; 50 mM Tris-HCl pH 7.4, 1%
NP 40, 0.25% sodium deoxycholate, 150 mM NaCl, 1
mM EGTA, 1 mM sodium orthovanadate, 1 mM sodium
fluoride, 1 mM phenylmethanesulphonyl fluoride, 10%
v/v of 100 × protease inhibitor cocktail from CalBio-
Chem) for Western Blots and in GPMIB for subsequent
DNA analyses.
Isolation of nucleic acids and protein from gradient 
purified mitochondria
Gradient purified mitochondrial pellets were sonicated
until completely dissolved before nucleic acid and protein
isolation. Nucleic acids were isolated from gradient puri-
fied mitochondria using the AllPrep DNA/RNA Mini Kit
from Qiagen using 600 μL Buffer RLT Plus. mtDNA quan-
tification was performed using the Quant-iT dsDNA Assay
Kit by Invitrogen and measured on a TECAN Genios Pro
96-well plate optical reader. For protein isolation, the
mitochondrial pellets were sonicated until dissolved and
vortexed every 5 min for 30 min while held on ice. The
samples were centrifuged at 15,000 × g for 10 min at 4°C
and supernatants containing the soluble protein fractions
were collected. Protein quantification was performed
using the Detergent Compatible Protein Assay Kit by Bio-
Rad with BSA standards and measured using an OptiMax
96-well plate optical reader at 750 nm.
Estimation of Heteroplasmic Mutations in mtDNA using 
Surveyor Nuclease
~2 kbase amplicons of the mtDNA coding region used
primers A-H as described in Bannwarth, et al. [24] qPCR
conditions for these amplicons used SybrGreen detection
and 25 nM [primers]; cycle conditions were 95°C for 3
min, then 50 cycles of 95°C for 30 sec, 57°C for 30 sec,
72°C for 4 min. Circular mtDNA standards for qPCR
analysis of amplicons from these primers were made from
Roche human genomic DNA treated with Plasmid-Safe
exonuclease followed by purification on Mobio columns.
Roche genomic DNA served as the standard for qPCR
assays of 18S rRNA gene. Human fetal brain total RNA
(Clontech) was reverse transcribed into cDNA and used as
a qPCR standard for estimation of relative PGC-1α levels
in brain cDNA samples, which were generated with iScript
reverse transcriptase (BioRad).
Surveyor Nuclease® Assay for mtDNA Mismatches
The concentration of DNA in amplicons from primers A-
H was estimated after separation on a 0.8% E-gel and
comparing with the Gel-Doc (BioRad) their band inten-
sity to the intensity of the bands in the 1 kb ladder whose
concentration is known. 400 ng of amplicon DNA was
mixed with 2 ul of "Enhancer" and 2 ul Surveyor Nucle-
ase® to 0.2 mL PCR tubes on ice that were then mixed and
incubated at 42°C for 60 min. Tubes were then trans-
ferred to ice and 2 ul of Stop Solution added. Controls
(undigested amplicons) were run alongside their corre-
sponding digests on 12K DNA chips (Experion®, BioRad).
The Experion® software calculated both bp size of DNA
bands and their concentrations.
Incubation of mtDNA with hOGG1 and quantification of 
8-oxoG levels by qPCR
Incubation of mtDNA containing oxidized 8-oxoG resi-
dues with hOGG1 is predicted to produce an apurinic site
at the site of oxidation due to hOGG1's N-glycosylase
activity. When PCR is initiated, the Taq polymerase is una-
ble to amplify past the 8-oxoG cleavage site where there is
a single-stranded break in the DNA sugar-phosphate back-
bone, thus interrupting PCR amplification. Due to this
phenomenon, it would be expected that undigested
mtDNA would appear to have a larger starting quantity
after qPCR when compared to the mtDNA from the same
sample treated with hOGG1 prior to qPCR, if it is believed
that the mtDNA does indeed suffer from 8-oxoG oxida-
tion. Enzymatic incubation occurred in a 20 μL reaction
volume containing 100 ng of mtDNA, 1 unit of hOGG1,
1 × Reaction Buffer (10 mM Tris-HCl, 50 mM NaCl, 10
mM MgCl2, 1 mM dithiothreitol, pH 7.9 at 25°C), and
100 μg/mL bovine serum albumin obtained from New
England BioLabs. Incubation occurred at 37°C for 1 hour
followed by 20 min of heat inactivation in a water bath at
90°C. All PD and CTL samples underwent incubation
conditions with and without hOGG1 where matched
undigested samples replaced the 1 unit of hOGG1 with a
matching volume of 1 × Reaction Buffer. Quantitative
PCR was performed in a 25 μL reaction volume using 5 ng
of ± hOGG1 treated mtDNA sample, 0.25 μM sense/anti-
sense primers, and 1 × iQ SYBR Green Supermix (2 × reac-
tion buffer with dNTPs, iTaq DNA polymerase, 6 mM
MgCl2, SYBR Green I, fluorescein, and stabalizers) from
Bio-Rad. Eight primer sets developed by Bannwarth et. al
labeled A-H were used and each contained ~2000 bp
encircling the sense-coding portion of the mitochondrial
genome (Figure 1) [26]. Quantitative PCR protocol con-
sisted of 40 cycles with 95°C denaturation, 57°C anneal-
ing, and 72°C elongation on an iQ5 Real Time PCR
Detection System by Bio-Rad, which contained software
to calculate starting quantity from measured cycle thresh-
old.
Immunoblot for Complex I-V and Subunits of Complex I
In a 30 μL reaction volume, 25 μg of purified mitochon-
drial protein was added to 10 μL XT working sample
buffer (XT Reducing Agent, XT Sample Buffer from Bio-Molecular Neurodegeneration 2009, 4:37 http://www.molecularneurodegeneration.com/content/4/1/37
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Rad) and heated for 5 min at 95°C. Electrophoresis was
performed using a 12-well 12% polyacrylamide Criterion
XT Bis-Tris Precast Gel with 1 × XT MES Running Buffer.
Precision Plus Dual Color Protein Standard containing 10
MW markers (10 kDa - 250 kDa) from Bio-Rad was used
to monitor the progression of the sample down the elec-
trophoretic gel. The iBlot Dry Blotting System from Invit-
rogen was used in the Western Blotting transfer of protein
from the polyacrylamide gel to nitrocellulose. The nitro-
cellulose was washed for 3 min with phosphate buffered
saline (PBS) and incubated at room temperature for 1
hour in Li-Cor Blocking Buffer. The blot was then placed
in the primary antibody solution for 1 hour at room tem-
perature. The primary antibody solution for the subunits
of Complex I was made of 20 μL Li-Cor Blocking Buffer
and contained 0.1% Tween 20 (polyoxyethylenesorbitan
monolaurate from Bio-Rad), 0.5 μg/mL rabbit anti-SOD2
antibody (Abcam), and the following mouse monoclonal
antibodies from MitoSciences: 1 μg/mL Complex I subu-
nit 8 kDa, 0.5 μg/mL Complex I subunit NDUFB4 (15
kDa), 0.5 μg/mL Complex I subunit NDUFB8 (20 kDa),
0.5 μg/mL Complex I subunit NDUFS3 (30 kDa), 1.125
μg/mL Complex I subunit NDUFA9 (39 kDa). The pri-
mary antibody solution for Complex I-V was made of 20
μL Li-Cor Blocking Buffer and contained 0.1% Tween 20
(Bio-Rad), 0.5 μg/mL rabbit anti-SOD2 antibody
(Abcam), and the following mouse monoclonal antibod-
ies from MitoSciences: 0.5 μg/mL Complex I subunit
NDUFB8 and 1:570 dilution of the MitoProfile Total
OXPHOS Human WB Antibody Cocktail containing
Complex I subunit NDUFB8, Complex II-FeS subunit 30
kDa, Complex III subunit Core 2, Complex IV subunit II,
ATP synthase subunit alpha. After 1 hour exposure to the
primary antibody solution the blot was washed 4 times
for 5 min each in PBS with 0.1% Tween 20 (T-PBS). Next,
the nitrocellulose was incubated for 30 min at room tem-
perature in 20 mL of secondary antibody solution made of
Li-Cor Blocking Buffer which contained 0.1% Tween 20,
33 μL 12% SDS, 1:7500 dilution of IRDye CW 800 goat
anti-mouse antibody (Li-Cor) and 1:4200 dilution of
IRDye CW 680 goat anti-rabbit antibody (Li-Cor). Blots
were washed 4 times for 5 min with T-PBS. The Western
Blots were repeated using the same protocol, but with a
primary antibody solution containing 1 μg/mL mouse
anti-Porin antibody (MitoSciences) and 0.5 μg/mL rabbit
anti-SOD2 antibody (Abcam). Western blots were visual-
ized using a Li-Cor Odyssey Infrared Imaging System,
which contained software to quantify protein amounts
based on calculated integrated intensities.
Amplex Red Assay for NADH-driven ROS Production in 
Postmortem Brain Mitochondria
This assay was described in our earlier publication [20]. It
is based on using NADH to drive electrons through mito-
chondrial complex I and into the ETC. Electrons leaving
the ETC react with ambient oxygen to form superoxide,
which is then dismutated to hydrogen peroxide by both
endogenous mitochondrial SOD2 and added SOD1. The
hydrogen peroxide formed, with added catalase, oxidizes
Amplex Red dye to a fluorescent derivative. The rate of
oxidized Amplex Red product formed over time is assayed
in a plate reader at 37 degrees.
Statistical Analyses
Statistical analyses were performed using InStat software
from GraphPad and JMP8 software from SAS Institute Inc.
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